Effects of infliximab against carbon tetrachloride-induced spleen toxicity in rats

Eur Rev Med Pharmacol Sci. 2023 Feb;27(3):1140-1146. doi: 10.26355/eurrev_202302_31220.

Abstract

Objective: Carbon tetrachloride (CCl4) is a non-polar molecule used in industry in grain curing, insect-killing and especially in the production of chlorofluorocarbons. It is estimated that an average of 70,000 industry workers in Europe are exposed to this toxic compound.

Materials and methods: Twenty-four male Sprague-Dawley rats were randomly allocated into four groups: control group (saline only, Group I), infliximab (INF) group (Group II), CCl4 group (Group III) and CCl4+INF group (Group IV).

Results: While there was an increase in the numerical density of CD3, CD68, and CD200R positive T lymphocytes and macrophages in the CCl4 administration group (p=0.000), this was not the case in the CCl4+INF administration group (p=0.000).

Conclusions: TNF-α inhibitors have a protective effect against CCl4-induced spleen toxicity/inflammation as seen by the reduction in CD3, CD68, CD200R positive T lymphocytes and macrophages.

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Carbon Tetrachloride*
  • Infliximab
  • Liver / metabolism
  • Male
  • Oxidative Stress
  • Plant Extracts / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Spleen*

Substances

  • Infliximab
  • Carbon Tetrachloride
  • Antioxidants
  • Plant Extracts